Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
7 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
15 authors at 6 institutions in 5 countries.
Sandra Medrano-GarciaMax Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Member of the Cardio-Pulmonary Institute (CPI), 61231 Bad Nauheim, Germany.ORCID 0000-0003-2802-2327
Daniel Morales-CanoDepartment of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Enfermedades Respiratorias, 28040 Madrid, Spain.ORCID 0000-0002-1692-4633
Bianca BarreiraDepartment of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Enfermedades Respiratorias, 28040 Madrid, Spain.
Alba Vera-ZambranoDepartment of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Enfermedades Respiratorias, 28040 Madrid, Spain.ORCID 0000-0002-4040-1920
Rahul KumarDepartment of Medicine, University of California, San Francisco, CA 94143, USA.
Djuro KosanovicDepartment of Pulmonology, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia.
Ralph Theo SchermulyDepartment of internal Medicine, Justus-Liebig University, Member of the German Center for Lung Research (DZL), 35305 Giessen, Germany.
Brian B GrahamDepartment of Medicine, University of California, San Francisco, CA 94143, USA.
Francisco Perez-VizcainoDepartment of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Enfermedades Respiratorias, 28040 Madrid, Spain.ORCID 0000-0001-6309-7418
Alistair MathieMedway School of Pharmacy, University of Kent and University of Greenwich, Chatham ME4 4BF, UK.ORCID 0000-0001-6094-2890
Rajkumar SavaiMax Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Member of the Cardio-Pulmonary Institute (CPI), 61231 Bad Nauheim, Germany.ORCID 0000-0003-1538-2091
Soni PullamsetiMax Planck Institute for Heart and Lung Research, Member of the German Center for Lung Research (DZL), Member of the Cardio-Pulmonary Institute (CPI), 61231 Bad Nauheim, Germany.ORCID 0000-0003-0440-8831
Ghazwan ButrousMedway School of Pharmacy, University of Kent and University of Greenwich, Chatham ME4 4BF, UK.
Edgar Fernández-MalavéDepartment of Immunology, Ophthalmology and ENT, Complutense University School of Medicine and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), 28040 Madrid, Spain.
Angel CogolludoDepartment of Pharmacology and Toxicology, School of Medicine, Universidad Complutense de Madrid and Instituto de Investigación Sanitaria Gregorio Marañón, Centro de Investigación Biomédica en Red Enfermedades Respiratorias, 28040 Madrid, Spain.ORCID 0000-0002-1382-1698
Universidad Complutense de Madrid · ESJustus-Liebig-Universität Gießen · DEMedway School of Pharmacy · GBUniversity of California, San Francisco · USResearch Institute Hospital 12 de Octubre · ESSechenov University · RU
Funding
Role of Complement-Driven Pulmonary Vascular Inflammation in PHP01HL152961 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI DELANEY, CASSIDY A · 2020 to 2024
$14.1M
Investigating paclitaxel treatment in a pre-clinical model of Schistosoma-pulmonary hypertensionR01HL135872 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI Brian Barkley Graham · 2017 to 2026
HIV and Schistosoma infections have been individually associated with pulmonary vascular disease. Co-infection with these pathogens is very common in tropical areas, with an estimate of six million people co-infected worldwide. However, the effects of HIV and Schistosoma co-exposure on the pulmonary vasculature and its impact on the development of pulmonary vascular disease are largely unknown. Here, we have approached these questions by using a non-infectious animal model based on lung embolization of
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
HIV and Schistosoma Co-Exposure Leads to Exacerbated Pulmonary Endothelial Remodeling and Dysfunction Associated with Altered Cytokine Landscape. · full record | Socratic